Ocuphire/Opus Merger Creates Public Retinal Gene Therapy Firm

Ocuphire will shift toward gene therapy for inherited retinal degeneration via a merger that will take Opus Genetics public. The firm will also be responsible for one of Ocuphire’s pipeline projects.